KEGG   DRUG: AsparaginaseHelp
Entry
D02997                      Drug                                   

Name
Asparaginase (USAN);
L-Asparaginase (JAN);
Asparaginase Erwinia chrysanthemi (USAN);
Elspar (TN)
Product
Source
Escherichia coli [TAX:562] (JAN), Erwinia chrysanthemi [TAX:556] (USAN)
Remark
Therapeutic category: 4291
ATC code: L01XX02
Product: D02997<JP/US>
Efficacy
Antineoplastic, Enzyme (L-asparaginase)
  Disease
Acute lymphoblastic leukemia [DS:H00001 H00002]
Comment
PEG-L-asparaginase
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XX Other antineoplastic agents
     L01XX02 Asparaginase
      D02997  Asparaginase (USAN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D02997  Asparaginase (USAN); L-Asparaginase (JAN); Asparaginase Erwinia chrysanthemi (USAN)
Antineoplastics [br08340.html]
 D02997
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D02997
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D02997
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D02997
BRITE hierarchy
Other DBs
CAS: 9015-68-3
PubChem: 17397153
DrugBank: DB00023
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system